{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:02:37Z","timestamp":1793908957056,"version":"4.8.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T00:00:00Z","timestamp":1534809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41391-018-0079-0","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T09:55:18Z","timestamp":1534845318000},"page":"24-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":309,"title":["Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations"],"prefix":"10.1038","volume":"22","author":[{"given":"E. David","family":"Crawford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio C. L.","family":"Pompeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Mendoza-Valdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans M. J.","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"79_CR1","unstructured":"Key statistics for prostate cancer. American Cancer Society; 2016."},{"key":"79_CR2","unstructured":"Cancer stat facts: common cancer sites. National Cancer Institute Surveillance, Epidemiology, End Results Program. National Institute of Health; 2017."},{"key":"79_CR3","unstructured":"Cancer stat facts: prostate cancer. National Cancer Institute Surveillance, Epidemiology, and End Results Program. National Institute of Health; 2017."},{"key":"79_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0021-9681(75)90029-6","volume":"28","author":"IT Higgins","year":"1975","unstructured":"Higgins IT. The epidemiology of cancer of the prostate. J Chronic Dis. 1975;28:343.","journal-title":"J Chronic Dis"},{"key":"79_CR5","first-page":"113","volume":"14","author":"G Wilding","year":"1992","unstructured":"Wilding G. The importance of steroid hormones in prostate cancer. Cancer Surv. 1992;14:113\u2013130.","journal-title":"Cancer Surv"},{"key":"79_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10555-013-9474-0","volume":"33","author":"Z Culig","year":"2014","unstructured":"Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. Cancer Metastas- Rev. 2014;33:413\u2013427.","journal-title":"Cancer Metastas- Rev"},{"key":"79_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0090-4295(00)00793-7","volume":"56","author":"MG Oefelein","year":"2000","unstructured":"Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56:1021\u20131024.","journal-title":"Urology"},{"key":"79_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12672-014-0173-2","volume":"5","author":"M Isikbay","year":"2014","unstructured":"Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5:72\u201389.","journal-title":"Horm Cancer"},{"key":"79_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fonc.2014.00370","volume":"4","author":"M Nouri","year":"2014","unstructured":"Nouri M, Ratther E, Stylianou N, Nelson CC, Hollier BG, Williams ED. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol. 2014;4:370.","journal-title":"Front Oncol"},{"key":"79_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.euf.2016.11.012","volume":"2","author":"Y Ceder","year":"2016","unstructured":"Ceder Y, Bjartell A, Culig Z, Rubin MA, Tomlins S, Visakorpi T. The molecular evolution of castration-resistant prostate cancer. Eur Urol Focus. 2016;2:506\u2013513.","journal-title":"Eur Urol Focus"},{"key":"79_CR11","first-page":"273","volume":"2","author":"V Parimi","year":"2014","unstructured":"Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014;2:273\u2013285.","journal-title":"Am J Clin Exp Urol"},{"key":"79_CR12","doi-asserted-by":"crossref","first-page":"101042831769225","DOI":"10.1177\/1010428317692259","volume":"39","author":"J Hu","year":"2017","unstructured":"Hu J, Wang G, Sun T. Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives. Tumour Biol. 2017;39:1010428317692259.","journal-title":"Tumour Biol"},{"issue":"Suppl 3","key":"79_CR13","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.3747\/co.19.1298","volume":"19","author":"L Klotz","year":"2012","unstructured":"Klotz L, Toren P. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? Curr Oncol. 2012;19(Suppl 3):S13\u201321.","journal-title":"Curr Oncol"},{"key":"79_CR14","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1464-410X.2009.08814.x","volume":"105","author":"M Perachino","year":"2010","unstructured":"Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int. 2010;105:648\u2013651.","journal-title":"BJU Int"},{"key":"79_CR15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz L, O\u2019Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015;33:1151\u20131156.","journal-title":"J Clin Oncol"},{"key":"79_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fendo.2017.00187","volume":"8","author":"C Grundker","year":"2017","unstructured":"Grundker C, Emons G. The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis. Front Endocrinol. 2017;8:187.","journal-title":"Front Endocrinol"},{"key":"79_CR17","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1158\/1078-0432.CCR-12-0931","volume":"19","author":"R Ferraldeschi","year":"2013","unstructured":"Ferraldeschi R, Sharifi N, Auchus RJ, Attard G. Molecular pathways: inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res. 2013;19:3353\u20133359.","journal-title":"Clin Cancer Res"},{"key":"79_CR18","unstructured":"Crona DJ, Whang YE. Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers 2017;9:18."},{"key":"79_CR19","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1002\/jcb.25928","volume":"118","author":"H Liu","year":"2017","unstructured":"Liu H, Wang L, Tian J, Li J, Liu H. Molecular dynamics studies on the enzalutamide resistance mechanisms induced by androgen receptor mutations. J Cell Biochem. 2017;118:2792\u20132801.","journal-title":"J Cell Biochem"},{"key":"79_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1040-8428(00)00051-2","volume":"35","author":"F Boccardo","year":"2000","unstructured":"Boccardo F. Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy? Crit Rev Oncol Hematol. 2000;35:121\u2013132.","journal-title":"Crit Rev Oncol Hematol"},{"key":"79_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467\u2013479.","journal-title":"Eur Urol"},{"key":"79_CR22","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0022-5347(05)67032-2","volume":"164","author":"P Iversen","year":"2000","unstructured":"Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol. 2000;164:1579\u20131582.","journal-title":"J Urol"},{"key":"79_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0303-7207(85)90013-9","volume":"41","author":"BA Cooke","year":"1985","unstructured":"Cooke BA, Sullivan MH. The mechanisms of LHRH agonist action in gonadal tissues. Mol Cell Endocrinol. 1985;41:115\u2013122.","journal-title":"Mol Cell Endocrinol"},{"key":"79_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.urology.2012.01.092","volume":"80","author":"JE Damber","year":"2012","unstructured":"Damber JE, Tammela TL, Iversen P, Abrahamsson PA, Boccon-Gibod L, Olesen TK, et al. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. Urology. 2012;80:174\u2013180.","journal-title":"Urology"},{"key":"79_CR25","unstructured":"LUPRON DEPOT\u00ae (leuprolide acetate for depot suspension) [prescribing information]. North Chicago, IL, USA: Abbott Laboratories; 2016."},{"key":"79_CR26","unstructured":"ELIGARD\u00ae (leuprolide acetate for injectable suspension) [prescribing information]. Fort Collins, CO, USA: Tolmar Pharmaceuticals Inc; 2017."},{"key":"79_CR27","unstructured":"TRELSTAR\u00ae (triptorelin pamoate injection, powder, lyophilized, for suspension) [prescribing information]. Parsippany, NJ, USA: Actavis Pharma, Inc.; 2014."},{"key":"79_CR28","unstructured":"ZOLADEX\u00ae (goserelin acetate implant) 10.8\u2009mg [prescribing information]. Lake Forest, IL, USA: TerSera Therapeutics; 2017."},{"key":"79_CR29","unstructured":"ZOLADEX\u00ae (goserelin acetate implant) 3.6\u2009mg [prescribing information]. Lake Forest, IL, USA: TerSera Therapeutics; 2016."},{"key":"79_CR30","unstructured":"Vantas\u2122 (histrelin implant) [prescribing information]. Newbury, NJ, USA: Valera Pharmaceuticals, Inc.; 2014."},{"key":"79_CR31","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1517\/17425255.2015.1073711","volume":"11","author":"ED Crawford","year":"2015","unstructured":"Crawford ED, Moul JW, Sartor O, Shore ND. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng\/dl. Expert Opin Drug Metab Toxicol. 2015;11:1465\u20131474.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"79_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bju.13482","volume":"119","author":"ND Shore","year":"2017","unstructured":"Shore ND, Chu F, Moul J, Saltzstein D, Concepcion R, McLane JA, et al. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int. 2017;119:239\u2013244.","journal-title":"BJU Int"},{"key":"79_CR33","first-page":"159","volume":"8","author":"A Spitz","year":"2016","unstructured":"Spitz A, Gittelman M, Karsh LI, Dragnic S, Soliman AM, Lele A, et al. Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng\/dL threshold: a retrospective analysis of two Phase III studies. Res Rep Urol. 2016;8:159\u2013164.","journal-title":"Res Rep Urol"},{"key":"79_CR34","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S0090-4295(01)01342-5","volume":"58","author":"D McLeod","year":"2001","unstructured":"McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001;58:756\u2013761.","journal-title":"Urology"},{"key":"79_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jcma.2012.04.010","volume":"75","author":"CC Kao","year":"2012","unstructured":"Kao CC, Chang YH, Wu T, Sun GH, Yu DS, Chang SY, et al. Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer. J Chin Med Assoc. 2012;75:255\u2013261.","journal-title":"J Chin Med Assoc"},{"key":"79_CR36","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s11255-012-0134-z","volume":"44","author":"E Dias Silva","year":"2012","unstructured":"Dias Silva E, Ferreira U, Matheus W, Faria EF, Silva GD, Saito M, et al. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. Int Urol Nephrol. 2012;44:1039\u20131044.","journal-title":"Int Urol Nephrol"},{"key":"79_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1756287217738150","volume":"10","author":"D Saltzstein","year":"2017","unstructured":"Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S. et al. Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. Ther Adv Urol. 2017;10:43\u201350.","journal-title":"Ther Adv Urol"},{"key":"79_CR38","unstructured":"Saltzstein D, McLane JA, Atkinson S, Boldt-Houle D, Renzulli JF. Biodegradable polymer-delivered, subcutaneously administered leuprolide acetate consistently achieved low nadir testosterone levels \u22645 ng\/dL. 28th Annual International Prostate Cancer Update; Beaver Creek, CO."},{"key":"79_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","volume":"57","author":"BJ Kiratli","year":"2001","unstructured":"Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57:127\u2013132.","journal-title":"Urology"},{"key":"79_CR40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1210\/jcem-66-2-314","volume":"66","author":"S Moorjani","year":"1988","unstructured":"Moorjani S, Dupont A, Labrie F, Lupien PJ, Gagne C, Brun D, et al. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab. 1988;66:314\u2013322.","journal-title":"J Clin Endocrinol Metab"},{"key":"79_CR41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/0026-0495(90)90297-P","volume":"39","author":"JC Seidell","year":"1990","unstructured":"Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39:897\u2013901.","journal-title":"Metabolism"},{"key":"79_CR42","first-page":"626","volume":"23","author":"ED Crawford","year":"2009","unstructured":"Crawford ED, Hou AH. The role of LHRH antagonists in the treatment of prostate cancer. Oncology. 2009;23:626\u2013630.","journal-title":"Oncology"},{"key":"79_CR43","unstructured":"Firmagon\u00ae (degarelix for injection) [prescribing information]. Parsippany, NJ, USA: Ferring Pharmaceuticals; 2016."},{"key":"79_CR44","unstructured":"Plenaxis (abarelix for injectable suspension) [Physician package insert]. Little Falls, NJ, USA: Praecis Pharmaceuticals, Inc.; 2001."},{"key":"79_CR45","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531\u20131538.","journal-title":"BJU Int"},{"key":"79_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000442848","volume":"9","author":"N Soga","year":"2016","unstructured":"Soga N, Kageyama T, Ogura Y, Yamada T, Hayashi N. Clinical effect of switching from a luteinizing hormone-releasing hormone agonist to an antagonist in patients with castration-resistant prostate cancer and serum testosterone level >\/=20 ng\/dl. Curr Urol. 2016;9:31\u201335.","journal-title":"Curr Urol"},{"key":"79_CR47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1464-410X.2011.10708.x","volume":"110","author":"MB Garnick","year":"2012","unstructured":"Garnick MB, Mottet N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int. 2012;110:499\u2013504.","journal-title":"BJU Int"},{"key":"79_CR48","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.eururo.2013.12.063","volume":"66","author":"L Klotz","year":"2014","unstructured":"Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66:1101\u20131108.","journal-title":"Eur Urol"},{"key":"79_CR49","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565\u2013573.","journal-title":"Eur Urol"},{"key":"79_CR50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/1758834017698644","volume":"9","author":"ED Crawford","year":"2017","unstructured":"Crawford ED, Shore ND, Petrylak DP, Higano CS, Ryan CJ. Abiraterone acetate and prednisone in chemotherapy-naive prostate cancer patients: rationale, evidence and clinical utility. Ther Adv Med Oncol. 2017;9:319\u2013333.","journal-title":"Ther Adv Med Oncol"},{"key":"79_CR51","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","volume":"32","author":"ME Taplin","year":"2014","unstructured":"Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32:3705\u20133715.","journal-title":"J Clin Oncol"},{"key":"79_CR52","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Eng J Med. 2011;364:1995\u20132005.","journal-title":"N Eng J Med"},{"key":"79_CR53","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"79_CR54","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Eng J Med. 2017;377:352\u2013360.","journal-title":"N Eng J Med"},{"key":"79_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Eng J Med. 2017;377:338\u2013351.","journal-title":"N Eng J Med"},{"key":"79_CR56","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","volume":"17","author":"ND Shore","year":"2016","unstructured":"Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung DP. et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17:153\u2013163.","journal-title":"Lancet Oncol"},{"key":"79_CR57","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","volume":"34","author":"DF Penson","year":"2016","unstructured":"Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol. 2016;34:2098\u20132106.","journal-title":"J Clin Oncol"},{"key":"79_CR58","unstructured":"ZYTIGA\u00ae (abiraterone acetate) Tablets [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2018."},{"key":"79_CR59","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng J Med. 2012;367:1187\u20131197.","journal-title":"N Eng J Med"},{"key":"79_CR60","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Eng J Med. 2014;371:424\u2013433.","journal-title":"N Eng J Med"},{"key":"79_CR61","unstructured":"Xtandi\u00ae (enzalutamide). Northbrook, IL USA: Astellas Pharma US, Inc.; 2017."},{"key":"79_CR62","unstructured":"ERLEADA\u2122 (apalutamide) tablets, for oral use. Highlights of prescribing information. Horsham, PA: Janssen Pharmaceutical Companies; 2018."},{"key":"79_CR63","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(14)70240-2","volume":"15","author":"K Fizazi","year":"2014","unstructured":"Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15:975\u2013985.","journal-title":"Lancet Oncol"},{"key":"79_CR64","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1210\/jc.2015-2770","volume":"100","author":"DB MacLean","year":"2015","unstructured":"MacLean DB, Shi H, Faessel HM, Saad F. Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): phase 1 study in healthy males. J Clin Endocrinol Metab. 2015;100:4579\u20134587.","journal-title":"J Clin Endocrinol Metab"},{"key":"79_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3322\/caac.20004","volume":"59","author":"K Ruddy","year":"2009","unstructured":"Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56\u201366.","journal-title":"CA Cancer J Clin"},{"key":"79_CR66","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.juro.2010.10.055","volume":"185","author":"N Lawrentschuk","year":"2011","unstructured":"Lawrentschuk N, Fernandes K, Bell D, Barkin J, Fleshner N. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol. 2011;185:848\u2013854.","journal-title":"J Urol"},{"key":"79_CR67","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618\u2013629.","journal-title":"Eur Urol"},{"key":"79_CR68","first-page":"2275","volume":"50","author":"N Bruchovsky","year":"1990","unstructured":"Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990;50:2275\u20132282.","journal-title":"Cancer Res"},{"key":"79_CR69","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Eng J Med. 2013;368:1314\u20131325.","journal-title":"N Eng J Med"},{"key":"79_CR70","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/21681805.2014.901410","volume":"48","author":"AJ Salonen","year":"2014","unstructured":"Salonen AJ, Taari K, Ala-Opas M, Sankila A, Viitanen J, Lundstedt S, et al. Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII. Scand J Urol. 2014;48:513\u2013522.","journal-title":"Scand J Urol"},{"key":"79_CR71","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.eururo.2015.10.007","volume":"69","author":"C Schulman","year":"2016","unstructured":"Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, et al. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (ICELAND). Eur Urol. 2016;69:720\u2013727.","journal-title":"Eur Urol"},{"key":"79_CR72","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","volume":"2","author":"DL Hershman","year":"2016","unstructured":"Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2:453\u2013461.","journal-title":"JAMA Oncol"},{"key":"79_CR73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13402-016-0268-6","volume":"39","author":"S Saini","year":"2016","unstructured":"Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol. 2016;39:97\u2013106.","journal-title":"Cell Oncol"},{"key":"79_CR74","first-page":"291","volume":"13","author":"M Shahidi","year":"2001","unstructured":"Shahidi M, Norman AR, Gadd J, Huddart RA, Horwich A, Dearnaley DP. Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol (R Coll Radiol). 2001;13:291\u2013295.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"79_CR75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/acta.0.0730011","volume":"73","author":"RS Swerdloff","year":"1973","unstructured":"Swerdloff RS, Walsh PC. Testosterone and oestradiol suppression of LH and FSH in adult male rats: duration of castration, duration of treatment and combined treatment. Acta Endocrinol (Copenh). 1973;73:11\u201321.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"79_CR76","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1464-410X.2009.08761.x","volume":"105","author":"J Morote","year":"2010","unstructured":"Morote J, Planas J, Ramirez C, Gomez E, Raventos CX, Placer J, et al. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int. 2010;105:481\u2013484.","journal-title":"BJU Int"},{"key":"79_CR77","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1464-410X.2009.08378.x","volume":"104","author":"J Morote","year":"2009","unstructured":"Morote J, Ramirez C, Gomez E, Planas J, Raventos CX, de Torres IM, et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int. 2009;104:486\u2013489.","journal-title":"BJU Int"},{"key":"79_CR78","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.juro.2011.12.063","volume":"187","author":"TM Sluis van der","year":"2012","unstructured":"van der Sluis TM, Bui HN, Meuleman EJ, Heijboer AC, Hartman JF, van Adrichem N, et al. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol. 2012;187:1601\u20131606.","journal-title":"J Urol"},{"key":"79_CR79","doi-asserted-by":"crossref","unstructured":"Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, et al. Serum testosterone levels in prostate cancer patients undergoing luteinizing hormone-releasing hormone agonist therapy. Clin Genitourin Cancer. 2018;16(2):e491\u2013e496.","DOI":"10.1016\/j.clgc.2017.10.025"},{"key":"79_CR80","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124\u2013137.","journal-title":"Eur Urol"},{"key":"79_CR81","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1464-410X.2011.10719.x","volume":"110","author":"B Djavan","year":"2012","unstructured":"Djavan B, Eastham J, Gomella L, Tombal B, Taneja S, Dianat SS, et al. Testosterone in prostate cancer: the Bethesda consensus. BJU Int. 2012;110:344\u2013352.","journal-title":"BJU Int"},{"key":"79_CR82","doi-asserted-by":"crossref","unstructured":"Prostate cancer: NCCN guidelines for prostate cancer updated. Nat Rev Urol. 2015;12:63.","DOI":"10.1038\/nrurol.2014.350"},{"key":"79_CR83","first-page":"28","volume":"21","author":"S Dason","year":"2014","unstructured":"Dason S, Allard CB, Wang JG, Hoogenes J, Shayegan B. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice. Can J Urol. 2014;21:28\u201336.","journal-title":"Can J Urol"},{"key":"79_CR84","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.juro.2015.03.120","volume":"194","author":"S Kamada","year":"2015","unstructured":"Kamada S, Sakamoto S, Ando K, Muroi A, Fuse M, Kawamura K, et al. Nadir testosterone after long-term follow up predicts prognosis in patients with prostate cancer treated with combined androgen blockade. J Urol. 2015;194:1264\u20131270.","journal-title":"J Urol"},{"issue":"4 Pt 1","key":"79_CR85","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.juro.2007.05.129","volume":"178","author":"J Morote","year":"2007","unstructured":"Morote J, Orsola A, Planas J, Trilla E, Raventos CX, Cecchini L, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178(4 Pt 1):1290\u20131295.","journal-title":"J Urol"},{"key":"79_CR86","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/bmj.290.6463.185","volume":"290","author":"SR Ahmed","year":"1985","unstructured":"Ahmed SR, Grant J, Shalet SM, Howell A, Chowdhury SD, Weatherson T, et al. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. BMJ. 1985;290:185\u2013187.","journal-title":"BMJ"},{"key":"79_CR87","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/pcan.2012.25","volume":"16","author":"ND Shore","year":"2013","unstructured":"Shore ND, Abrahamsson PA, Anderson J, Crawford ED, Lange P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013;16:7\u201315.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"79_CR88","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.juro.2008.07.033","volume":"180","author":"M Gittelman","year":"2008","unstructured":"Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK. Degarelix Study G. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol. 2008;180:1986\u20131992.","journal-title":"J Urol"},{"key":"79_CR89","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.eururo.2008.04.065","volume":"54","author":"H Poppel Van","year":"2008","unstructured":"Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold Olesen T. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008;54:805\u2013813.","journal-title":"Eur Urol"},{"key":"79_CR90","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1210\/jcem-66-2-308","volume":"66","author":"IT Huhtaniemi","year":"1988","unstructured":"Huhtaniemi IT, Dahl KD, Rannikko S, Hsueh AJ. Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy. J Clin Endocrinol Metab. 1988;66:308\u2013313.","journal-title":"J Clin Endocrinol Metab"},{"key":"79_CR91","first-page":"275","volume":"4","author":"MB Garnick","year":"2000","unstructured":"Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol. 2000;4:275\u2013277.","journal-title":"Mol Urol"},{"key":"79_CR92","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2016.71.4204","volume":"35","author":"DY Chen","year":"2017","unstructured":"Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC, et al. Risk of cardiovascular ischemic events after surgical castration and gonadotropin-releasing hormone agonist therapy for prostate cancer: a nationwide cohort study. J Clin Oncol. 2017;35:3697\u20133705.","journal-title":"J Clin Oncol"},{"key":"79_CR93","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","volume":"35","author":"ED Crawford","year":"2017","unstructured":"Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017;35:183\u2013191.","journal-title":"Urol Oncol"},{"key":"79_CR94","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1756287215617872","volume":"8","author":"P Zareba","year":"2016","unstructured":"Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8:118\u2013129.","journal-title":"Ther Adv Urol"},{"key":"79_CR95","doi-asserted-by":"crossref","unstructured":"Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol. 2015;33(9):1281\u20131289.","DOI":"10.1007\/s00345-014-1439-6"},{"key":"79_CR96","first-page":"7847","volume":"22","author":"J Barkin","year":"2015","unstructured":"Barkin J. Risks, benefits, and approaches to hormonal blockade in prostate cancer. Highlights from the European Association of Urology Meeting, March 20\u221224, 2015, Madrid, Spain. Can J Urol. 2015;22:7847\u20137852.","journal-title":"Can J Urol"},{"key":"79_CR97","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/jama.299.3.289","volume":"299","author":"AV D\u2019Amico","year":"2008","unstructured":"D\u2019Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289\u2013295.","journal-title":"JAMA"},{"key":"79_CR98","unstructured":"Scher H, Roe M. A trial comparing cardiovascular safety of Degarelix versus Leuprolide in patients with advanced prostate cancer and cardiovascular disease (PRONOUNCE). NIH U.S. National Library of Medicine; 2016."},{"key":"79_CR99","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2003.02.083","volume":"21","author":"SP Balk","year":"2003","unstructured":"Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21:383\u2013391.","journal-title":"J Clin Oncol"},{"key":"79_CR100","first-page":"385","volume":"1","author":"L Jia","year":"2003","unstructured":"Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res. 2003;1:385\u2013392.","journal-title":"Mol Cancer Res"},{"key":"79_CR101","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1093\/nar\/25.15.3143","volume":"25","author":"J Zhang","year":"1997","unstructured":"Zhang J, Zhang S, Murtha PE, Zhu W, Hou SS, Young CY. Identification of two novel cis-elements in the promoter of the prostate-specific antigen gene that are required to enhance androgen receptor-mediated transactivation. Nucleic Acids Res. 1997;25:3143\u20133150.","journal-title":"Nucleic Acids Res"},{"key":"79_CR102","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/annonc\/mdm332","volume":"18","author":"S Oudard","year":"2007","unstructured":"Oudard S, Banu E, Scotte F, Banu A, Medioni J, Beuzeboc P, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol. 2007;18:1828\u20131833.","journal-title":"Ann Oncol"},{"key":"79_CR103","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.urology.2006.03.055","volume":"68","author":"RC Semeniuk","year":"2006","unstructured":"Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology. 2006;68:565\u2013569.","journal-title":"Urology"},{"key":"79_CR104","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1021\/bi00076a020","volume":"32","author":"P Murtha","year":"1993","unstructured":"Murtha P, Tindall DJ, Young CY. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5\u2019 promoter region of the gene. Biochemistry. 1993;32:6459\u20136464.","journal-title":"Biochemistry"},{"key":"79_CR105","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2013.08.015","volume":"65","author":"M Khera","year":"2014","unstructured":"Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014;65:115\u2013123.","journal-title":"Eur Urol"},{"key":"79_CR106","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s00120-012-2948-9","volume":"51","author":"A Heidenreich","year":"2012","unstructured":"Heidenreich A, Porres D, Epplen R, van Erps T, Pfister D. [Change of the LHRH analogue in progressive castration-refractory prostate cancer]. Urol A. 2012;51:1282\u20131287.","journal-title":"Urol A"},{"key":"79_CR107","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/iju.13180","volume":"23","author":"J Morote","year":"2016","unstructured":"Morote J, Comas I, Planas J, Celma A, Ferrer R, Regis L. Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy. Int J Urol. 2016;23:957\u2013958.","journal-title":"Int J Urol"},{"key":"79_CR108","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1210\/jc.2003-032175","volume":"89","author":"AM Matsumoto","year":"2004","unstructured":"Matsumoto AM, Bremner WJ. Serum testosterone assays\u2014accuracy matters. J Clin Endocrinol Metab. 2004;89:520\u2013524.","journal-title":"J Clin Endocrinol Metab"},{"key":"79_CR109","unstructured":"Voelcker L, Maschmann R. Study of Abiraterone Acetate plus ADT versus APALUTAMIDE versus Abiraterone and APALUTAMIDE in patients with advanced prostate cancer with non-castrate testosterone levels. NIH U.S. National Library of Medicine; 2016."},{"key":"79_CR110","unstructured":"Taplin M-E. Neoadjuvant and adjuvant Abiraterone Acetate\u2009+\u2009Apalutamide prostate cancer undergoing prostatectomy. NIH U.S. National Library of Medicine; 2016."},{"key":"79_CR111","unstructured":"Efstathiou E. Effects of Apalutamide plus LHRH agonist or Apalutamide plus Abiraterone Acetate plus LHRH agonist for six months for prostate cancer patients at high risk for recurrence. NIH U.S. National Library of Medicine; 2017."},{"key":"79_CR112","unstructured":"Courtney KD. Enzalutamide and hormone therapy before, during, and after radiation for high risk localized prostate cancer. NIH U.S. National Library of Medicine; 2014."},{"key":"79_CR113","unstructured":"Pfizer. Safety and efficacy study of Enzalutamide plus Leuprolide in patients with nonmetastatic prostate cancer (EMBARK). NIH U.S. National Library of Medicine; 2014."},{"key":"79_CR114","unstructured":"Wacker M. Enzalutamide versus standard androgen deprivation therapy for the treatment hormone sensitive prostate cancer. NIH U.S. National Library of Medicine; 2014."},{"key":"79_CR115","unstructured":"Bayer. ODM-201 in addition to standard ADT and docetaxel in metastatic castration sensitive prostate cancer (ARASENS). NIH U.S. National Library of Medicine; 2016."},{"key":"79_CR116","unstructured":"Garcia, MD JA. ARN-509 and Leuprolide in intermediate and high-risk prostate cancer. NIH U.S. National Library of Medicine; 2016."},{"key":"79_CR117","unstructured":"Androgen receptor antagonist ARN-509 with or without Abiraterone Acetate, gonadotropin-releasing hormone analog, and Prednisone in treating patients with high-risk prostate cancer undergoing surgery. NIH U.S. National Library of Medicine; 2016."},{"key":"79_CR118","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Eng J Med. 2016;375:443\u2013453.","journal-title":"N Eng J Med"},{"key":"79_CR119","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and Olaparib in metastatic prostate cancer. N Eng J Med. 2015;373:1697\u20131708.","journal-title":"N Eng J Med"},{"key":"79_CR120","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.18632\/oncotarget.10547","volume":"7","author":"JN Graff","year":"2016","unstructured":"Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7:52810\u201352817.","journal-title":"Oncotarget"},{"issue":"1A Suppl","key":"79_CR121","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0090-4295(96)80006-9","volume":"47","author":"MS Soloway","year":"1996","unstructured":"Soloway MS, Schellhammer PF, Smith JA, Chodak GW, Kennealey GT. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Urology. 1996;47(1A Suppl):33\u201337. discussion 48\u221253","journal-title":"Urology"},{"key":"79_CR122","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1046\/j.0919-8172.2003.00601.x","volume":"10","author":"K Yoshimura","year":"2003","unstructured":"Yoshimura K, Sumiyoshi Y, Hashimura T, Ueda T, Kamiryo Y, Yamamoto A, et al. Neoadjuvant flutamide monotherapy for locally confined prostate cancer. Int J Urol. 2003;10:190\u2013195.","journal-title":"Int J Urol"},{"key":"79_CR123","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1046\/j.1464-410X.2003.04413.x","volume":"92","author":"V Serretta","year":"2003","unstructured":"Serretta V, Daricello G, Dispensa N, Allegro R, Pavone C, Pavone-Macaluso M. Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study. BJU Int. 2003;92:545\u2013549. discussion 549\u2013550","journal-title":"BJU Int"},{"key":"79_CR124","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/j.1464-410X.2005.05714.x","volume":"96","author":"M Nakabayashi","year":"2005","unstructured":"Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, et al. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int. 2005;96:783\u2013786.","journal-title":"BJU Int"},{"key":"79_CR125","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0090-4295(98)00129-0","volume":"52","author":"FJ Debruyne","year":"1998","unstructured":"Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, et al. Liarozole\u2014a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology. 1998;52:72\u201381.","journal-title":"Urology"},{"key":"79_CR126","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00345-013-1206-0","volume":"32","author":"PC Verhagen","year":"2014","unstructured":"Verhagen PC, Wildhagen MF, Verkerk AM, Vjaters E, Pagi H, Kukk L, et al. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial. World J Urol. 2014;32:1287\u20131294.","journal-title":"World J Urol"},{"key":"79_CR127","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/pcan.2011.50","volume":"15","author":"A Spitz","year":"2012","unstructured":"Spitz A, Young JM, Larsen L, Mattia-Goldberg C, Donnelly J, Chwalisz K. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2012;15:93\u201399.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"79_CR128","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2165\/11319690-000000000-00000","volume":"29","author":"EA Lundstrom","year":"2009","unstructured":"Lundstrom EA, Rencken RK, van Wyk JH, Coetzee LJ, Bahlmann JC, Reif S, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig. 2009;29:757\u2013765.","journal-title":"Clin Drug Investig"},{"key":"79_CR129","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s12325-016-0466-7","volume":"34","author":"J Breul","year":"2017","unstructured":"Breul J, Lundstrom E, Purcea D, Venetz WP, Cabri P, Dutailly P, et al. Efficacy of testosterone suppression with sustained-release triptorelin in advanced prostate cancer. Adv Ther. 2017;34:513\u2013523.","journal-title":"Adv Ther"},{"key":"79_CR130","doi-asserted-by":"crossref","unstructured":"Wilke D, Patil N, Hollenhorst H, Bowes D, Rutledge R, Ago C. Testosterone suppression with Luteinizing hormone-releasing hormone (LHRH) agonists in patients receiving radiotherapy for prostate cancer. Pharmacotherapy. 2018;38(3):327\u2013333.","DOI":"10.1002\/phar.2084"},{"key":"79_CR131","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","volume":"27","author":"G Attard","year":"2009","unstructured":"Attard G, Reid AH, A\u2019Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742\u20133748.","journal-title":"J Clin Oncol"},{"key":"79_CR132","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563\u20134571.","journal-title":"J Clin Oncol"},{"key":"79_CR133","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","volume":"70","author":"MR Smith","year":"2016","unstructured":"Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, et al. Phase 2 study of the safety and antitumor activity of Apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol. 2016;70:963\u2013970.","journal-title":"Eur Urol"},{"key":"79_CR134","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14656566.2017.1329820","volume":"18","author":"ND Shore","year":"2017","unstructured":"Shore ND. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother. 2017;18:945\u2013952.","journal-title":"Expert Opin Pharmacother"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0079-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0079-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0079-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:33:28Z","timestamp":1684618408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-018-0079-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["79"],"URL":"https:\/\/doi.org\/10.1038\/s41391-018-0079-0","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,21]]},"assertion":[{"value":"29 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"E.D.C. has held consulting or advisory roles for Bayer, Mdx, Genomic Health, Janssen, Dendreon, Ferring, and Tolmar, and has received grants from NIH and University of Colorado. A.H. has held consulting or advisory roles for Amgen, Astellas, Ferring, Ipsen, Jansen-Cilag, Pfizer, Sanofi, and Takeda. N.L. has held consulting or advisory roles for A&Z, Astellas, Ipsen, Janssen, and Tolmar. K.M. has held consulting or advisory roles for Amgen, Astellas, Bayer, BMS, Ferring, Janssen, Medivation, Merck, MSD, Novartis, Pfizer, Roche, and Tolmar. L.K. has received grants from Abbvie, Ferring, Sanofi, and Tersera. The remaining authors declare that they have no conflicts of interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}